Meaning
In-depth regulatory inquiries initiated by competition authorities evaluate complex corporate combinations that raise potential competition concerns during preliminary reviews. Entering a phase two investigation extends merger review timelines by several months while enforcement staff collect extensive evidentiary materials, customer testimony and market data. Regulators apply this detailed procedure when initial filings fail to rule out anti-competitive market concentration.
The investigation concludes when the agency issues a final approval decision, accepts structural remedies or prohibits the acquisition.
Evidence Gathering
Competition agencies deploy broad investigative powers to subpoena internal company communications, economic modeling and board presentations during phase two proceedings. Parties respond to detailed questionnaires regarding pricing algorithms, customer switching costs and market capacity metrics. Econometric analysis submitted during a phase two investigation tests whether proposed synergies outweigh market power gains resulting from entity consolidation.
Economic experts present econometric testimony to demonstrate that market entry barriers remain low enough to discipline post-merger pricing decisions.
Remedy Negotiation
Merging entities offer structural asset divestitures to resolve competition concerns identified during deep reviews. Agencies evaluate proposed buyer suitability before approving remedy packages.
Abandonment Risk
Prolonged regulatory scrutiny increases transaction risk by exhausting deal financing commitments and distracting company management. Acquirers often exercise contractual walk-away rights when phase two inquiries exceed long-stop dates.
